Daily Cardiology Research Analysis
Analyzed 108 papers and selected 3 impactful papers.
Summary
Analyzed 108 papers and selected 3 impactful articles.
Selected Articles
1. CAMK2D causes heart failure in mice with RBM20 cardiomyopathy.
Using genetic mouse models and pharmacologic inhibition, the study demonstrates that CAMK2D overactivation—not merely mis-splicing—drives cardiac dysfunction in RBM20 cardiomyopathy. Double knockout of Rbm20 and Camk2d rescues heart failure/sudden death, re-expression of CAMK2D isoforms reintroduces dysfunction, and CAMK2 inhibition (hesperadin) improves cardiac function in RBM20 mutant mice.
Impact: Identifies CAMK2D overactivation as a causal and druggable mechanism in a genotype-defined cardiomyopathy, enabling cause-directed therapeutic strategies.
Clinical Implications: Supports development of CAMK2D inhibitors for RBM20 cardiomyopathy and encourages genotype-guided trials testing CAMK2 pathway blockade as a precision therapy.
Key Findings
- Rbm20/Camk2d double knockout mice were protected from heart failure and sudden cardiac death.
- RBM20-deficient hearts showed increased phosphorylation of CAMK2D targets, indicating functional activation.
- Re-expression of individual CAMK2D splice variants reintroduced cardiac dysfunction.
- ATP-competitive CAMK2 inhibitor hesperadin improved cardiac function in Rbm20-p.Arg636Gln knock-in mice.
Methodological Strengths
- Multiple complementary in vivo genetic models (double knockout, knock-in) and rescue experiments.
- Pharmacologic validation of target with an ATP-competitive CAMK2 inhibitor demonstrating functional benefit.
Limitations
- Preclinical mouse models may not fully capture human disease heterogeneity.
- Target selectivity and safety of CAMK2 inhibition (e.g., hesperadin off-target effects) require clinical evaluation.
Future Directions: Initiate genotype-guided phase I/II trials of selective CAMK2D inhibitors in RBM20 cardiomyopathy; elucidate translational biomarkers of CAMK2D activity and arrhythmic risk modulation.
Although heart disease arises from different etiologies, treatment remains largely one-size-fits-all, leaving many patients without optimal benefit, which highlights the need for cause-directed therapies. Pathogenic variants in RBM20, a cardiac splicing factor, lead to an aggressive form of dilated cardiomyopathy with high risk of ventricular arrhythmias. We hypothesized that the splicing target calcium/calmodulin-dependent kinase II delta (CAMK2D) is disease causing in RBM20 cardiomyopathy. He
2. A nurse-coordinated intervention programme vs standard of care after an acute coronary syndrome: the ALLEPRE trial.
In 2,057 post-ACS patients, a multicenter pragmatic RCT showed that a nurse-coordinated prevention program reduced long-term MACE versus standard care (HR 0.70), driven by fewer nonfatal MIs (HR 0.60), and improved exercise, weight control, and medication adherence.
Impact: Demonstrates clinically meaningful, scalable benefits of a nurse-led secondary prevention model with hard cardiovascular outcomes.
Clinical Implications: Health systems should consider embedding structured nurse-coordinated secondary prevention into post-ACS pathways to reduce recurrent events and enhance adherence.
Key Findings
- Primary composite MACE reduced with NCPP vs SOC: 16.2% vs 22.6% (HR 0.70, 95% CI 0.57-0.85; p<0.001).
- Nonfatal MI significantly reduced: 9.3% vs 15.2% (HR 0.60, 95% CI 0.46-0.77; p=0.0001).
- Secondary composite (MACE + ischaemia-driven revascularization) reduced (HR 0.77, 95% CI 0.64-0.92; p=0.005).
- Behavioral metrics improved: exercise frequency (p<0.0001), weight control (p=0.003), medication adherence (p<0.001).
Methodological Strengths
- Pragmatic, multicenter randomized design with a large sample size (n=2057).
- Hard clinical endpoints with intention-to-treat analyses and behavior/adherence measures.
Limitations
- Open-label behavioral intervention may introduce performance bias.
- Intervention intensity and standardization across centers may vary, affecting generalizability.
Future Directions: Cost-effectiveness analyses across diverse health systems and implementation trials to optimize nurse training, frequency, and digital augmentations.
BACKGROUND AND AIMS: There is a lack of long-term outcome data supporting the role of nurses in cardiovascular (CV) risk management. The ALLEPRE [ALLiance for sEcondary PREvention after an acute coronary syndrome (ACS)] trial was a pragmatic, randomized, multicentre, interventional trial comparing the efficacy of a nurse-coordinated prevention program (NCPP) with standard of care (SOC). METHODS: The NCPP patients attended nine individual educational sessions over four years at which a centrally trained nurse provided counselling aimed at identifying CV risk factors and encouraging healthier lifestyles and medication adherence; the SOC patients followed the standard practices of their hospitals. The trial's primary endpoint was the composite of CV death, non-fatal myocardial infarction (MI), and non-fatal stroke (MACE). RESULTS: A total of 2057 ACS patients were randomized 1:1 to the NCCP (n=1031) or SOC group (n=1026). In comparison with SOC, the NCPP significantly reduced MACE [16.2% vs 22.6%; hazard ratio (HR) 0.70; 95% confidence interval (CI) 0.57-0.85; P-value <0.001], a benefit mainly driven by a reduction in non-fatal MI (9.3% vs 15.2%; HR 0.60; 95% CI 0.46-0.77; P-value=0.0001). The occurrence of the pre-specified secondary outcome of MACE plus ischaemia-driven revascularization was significantly reduced (HR 0.77, 95% CI 0.64-0.92; P-value= 0.005). Exercise frequency (P<0.0001), body weight control (P=0.003), and medication adherence (P<0.001) improved more in the NCPP group. CONCLUSIONS: The NCPP significantly reduced long-term MACE, improved physical activity, body weight control, and pharmacotherapy adherence in post-hospitalization ACS patients. Including an NCPP in healthcare provision may contribute to the successful implementation of secondary prevention strategies.
3. Long term outcomes of different revascularization strategies in left main coronary artery: a network meta-analysis.
Across 17 RCTs (n=7,700) in LMCA disease, angiography-guided PCI was associated with higher MACE versus imaging-guided PCI (IRR 1.34) and CABG (IRR 1.49), while imaging-guided PCI and CABG had comparable all-cause mortality. CABG reduced MI and repeat revascularization; imaging guidance reduced stent thrombosis/graft occlusion, and angiography-guided PCI had lower stroke than CABG and imaging guidance.
Impact: Elevates intravascular imaging from a procedural adjunct to a determinant of comparative effectiveness in LMCA PCI, directly informing Heart Team decision-making.
Clinical Implications: Prefer intravascular imaging guidance (IVUS/OCT) when performing LMCA PCI; CABG remains favorable for MI and repeat revascularization reduction. Angiography-only PCI should be avoided when feasible.
Key Findings
- Angiography-guided PCI increased MACE vs imaging-guided PCI (IRR 1.34, 95% CI 1.05-1.72) and vs CABG (IRR 1.49, 95% CI 1.10-2.03).
- All-cause death was similar between imaging-guided PCI and CABG (IRR 1.00, 95% CI 0.81-1.24).
- CABG reduced MI, target vessel revascularization, and repeat revascularization compared with PCI strategies.
- Imaging guidance reduced stent thrombosis or graft occlusion relative to comparators; angiography-guided PCI showed a lower stroke risk than CABG and imaging guidance.
Methodological Strengths
- Network meta-analysis restricted to randomized controlled trials with 7,700 patients.
- Comparative evaluation of angiography-guided PCI, imaging-guided PCI, and CABG with multiple hard endpoints.
Limitations
- Median follow-up of 2 years may not capture late divergences in outcomes.
- Heterogeneity in imaging protocols and endpoint definitions across trials.
Future Directions: Head-to-head RCTs standardizing intravascular imaging protocols in LMCA PCI with long-term follow-up; cost-effectiveness and stroke mechanisms analyses.
BACKGROUND: The comparative effectiveness of angiography-guided versus imaging-guided PCI relative to coronary artery bypass grafting (CABG) in left main coronary artery (LMCA) disease remains uncertain. METHODS: We performed a network meta-analysis of randomized controlled trials (RCTs) including patients undergoing LMCA revascularization. Pooled incidence rate ratios (IRRs) with 95% confidence intervals (CIs) were computed. Co-primary endpoints were major adverse cardiovascular events (MACE) by trial definition and all-cause death. Secondary endpoints included myocardial infarction (MI), stroke, target vessel revascularization (TVR), repeat revascularization, and stent thrombosis or graft occlusion. RESULTS: Seventeen RCTs encompassing 7700 patients (median follow-up 2 y